Login    Join free Add to favorites    中文
home > news > AMSBIO: Immunotherapy Used to Treat Aggressive Colon Tumors
Industry Updates | New Products | Supplier News | Upcoming Events | business | web
AMSBIO: Immunotherapy Used to Treat Aggressive Colon Tumors

hits:988     Date:03/05/18
AMSBIO reports on ground breaking research** by the Institute for Research in Biomedicine (IRB), Barcelona that cites use of its proprietary 3D organoid technology to develop a mouse model that mimics advanced human colon cancer. This model has allowed them to study the immune system response for the first time.

In a short space of time, therapies based on stimulating the immune system against cancer cells have become a powerful approach to treat cancers such as melanoma and lung cancer. However, to date, most colon tumors appeared to be unresponsive to this kind of therapy. In a newly published 6-year study, IRB Barcelona explains that the hormone TGF-beta is responsible for the 鈥渂lindness鈥 of the immune system to colon cancer cells. After development of the animal model, and confirming the similarity of the mouse tumours with those in humans, IRB Barcelona built a biobank of tumor organoids (3D mini-tumors) to then graft them in a controlled manner in immunocompetent mice. This animal model, which mimics the main features of metastatic colon cancer in patients, allowed the researchers to examine how cancer cells evade the immune system by increased levels of TGFß. This study paves the way for the development of TGFß directed immunotherapies for patients diagnosed with advanced colon cancer.

Eduard Batlle, of IRB Barcelona, commented 鈥淭he ability to culture and maintain tumor organoids has been key to the success of this research. Organoids offer multiple advantages as pre-clinical models for cancer research and drug testing鈥.

AMSBIO offers a unique range of matrices and other solutions for 3D cell culture including natural hydrogels, recombinant matrices, artificial scaffolds and scaffold-free systems. These matrices not only support cells and cell layers, but also play an essential role in tissue organization that affects cell adhesion, migration, proliferation, and differentiation. AMSBIO has also developed a comprehensive portfolio of leading edge products and offers ready to use cells for in vitro based T-cell mediated target tumor cell killing and assess the activity of immunotherapeutic agents.

These aspects can be studied with other products from AMSBIO such as quantitative, fluorescent tumor cell proliferation assays that measure the ability of your drug compounds to inhibit the proliferation of selected cancer cell lines. AMSBIO also offers patient-derived, in vitro cancer cell models and cell culture media that helps shed new light on the diversity, individuality, and complexity of the disease. Recently, AMSBIO pioneered a multidisciplinary approach combining expertise in microfluidics and 3D culture to develop a novel microfluidic platform for cancer research in collaboration with Strathclyde University, Glasgow. This new platform combines microfluidic lab-on-a-chip technology with physiologically relevant 3D spheroids to enable formation and long-term culture of 3D multicellular tumors / organoids for drug screening and individualized chemo sensitivity testing.

For further information on leading edge tools and services for cancer research please visit http://www.amsbio.com/organoids.aspx or contact AMSBIO on 44-1235-828200/ +1-617-945-5033 / info@amsbio.com.

Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products and services for research and development in the medical, nutrition, cosmetics and energy industries. AMSBIO can draw upon in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion and proliferation. Widely acknowledged as an expert in cell culture, AMSBIO partners with clients in tailoring cell systems to enhance organoid and spheroid type screening outcomes from a technological and cost-effective perspective.

** http://www.ngmbio.com/file.cfm/82/docs/Tauriello_2018_Nat_TGFb_CRC.pdf  

Worldwide HQ 

AMS Biotechnology (AMSBIO)
184 Milton Park
Oxon OX14 4SE
Tel: +44-1235-828200
Fax: +44-1235-820482
Email: info@amsbio.com 
Web www.amsbio.com
North American HQ
1035 Cambridge Street
MA 02141
Tel: +1.617.945.5033 
Tel: +1.800.987.0985 (toll free)
Email: info@amsbio.com 
Web www.amsbio.com
Related News>> more

Copyright(C) 2006-2018 Bio-Equip    E-mail:web@bio-equip.cn   娌狪CP澶06040519鍙